Loading
Entrectinib shrank tumours in more than three quarters of patients with ROS1-positive lung cancer and, unlike crizotinib, controlled brain metastases in most patients who had them, earning approval as a first-line option.
Integrated analysis of 53 ROS1 inhibitor-naive patients with ROS1 fusion-positive non-small-cell lung cancer from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.
Objective response was 77 percent with median duration of response 24.6 months and median progression-free survival 19.0 months; intracranial response was 55 percent in patients with brain metastases.
Entrectinib is a first-line ROS1 inhibitor with brain activity, preferred over crizotinib when brain metastases are present, though repotrectinib and taletrectinib now offer longer control.
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.
Shares Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme, Entrectinib, ROS1-positive non-small-cell lung cancer.
Shares Entrectinib, The Lancet Oncology.
Shares Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme, ROS1-positive non-small-cell lung cancer.
Shares Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme, Entrectinib, ROS1-positive non-small-cell lung cancer.
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.